3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 3
2
Phase NA
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
14
Leukemia
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Myelodysplastic Syndromes
10
Leukemia, Lymphocytic, Chronic, B-Cell
10
Lymphoma, Non-Hodgkin
9
Leukemia, Myeloid, Accelerated Phase
9
Multiple Myeloma
8
Leukemia, Myelomonocytic, Chronic
8
Leukemia, Myeloid, Chronic-Phase
8
Myeloproliferative Disorders
7
Lymphoma, Mantle-Cell
7
Lymphoma, Follicular
7
Hodgkin Disease
7
Congenital Abnormalities
7
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, B-Cell, Marginal Zone
6
Carcinoma, Renal Cell
6
Blast Crisis
6
Lymphoma, Large-Cell, Immunoblastic
5
Lymphoma
5
Burkitt Lymphoma
5
Thrombocythemia, Essential
4
Polycythemia Vera
4
Pdgfra-Associated Chronic Eosinophilic Leukemia
4
Myelodysplastic-Myeloproliferative Diseases
4
Lymphoma, T-Cell, Cutaneous
4
Leukemia, Neutrophilic, Chronic
4
Waldenstrom Macroglobulinemia
3
Sezary Syndrome
3
Interventions
Cyclophosphamide
19
fludarabine
18
Tacrolimus
10
Whole-Body Irradiation
9
Mycophenolic Acid
8
venetoclax
7
fludarabine phosphate
7
Sirolimus
7
Azacitidine
7
Mesna
5
Dexamethasone
5
Bortezomib
5
Rituximab
4
Methotrexate
4
Busulfan
4
daratumumab
3
Stem Cell Transplantation
3
Peripheral Blood Stem Cell Transplantation
3
Nivolumab
3
Melphalan
3
Lenalidomide
3
Filgrastim
3
Cytarabine
3
Biopsy
3
Alemtuzumab
3
AP 1903 reagent
3
pomalidomide
2
merphos
2
isatuximab
2
ibrutinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Hematologic Neoplasms
×
Cyclosporine
×
Clear all
NCT00058825
2016-11-07
HIMSUM
Baylor College of Medicine
Phase 1/2
Terminated
27 enrolled
13 charts